{"id":54586,"date":"2026-04-03T08:16:14","date_gmt":"2026-04-03T08:16:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/54586\/"},"modified":"2026-04-03T08:16:14","modified_gmt":"2026-04-03T08:16:14","slug":"novo-nordisk-wegovy-data-challenges-foundayo-and-resets-valuation-debate","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/54586\/","title":{"rendered":"Novo Nordisk Wegovy Data Challenges Foundayo And Resets Valuation Debate"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

Novo Nordisk released new cross trial data indicating its oral Wegovy pill produces greater weight loss than Eli Lilly\u2019s newly FDA approved obesity pill Foundayo.<\/p>\n

The company reports fewer adverse events with Wegovy compared with Foundayo and cites strong patient preference for Wegovy\u2019s treatment profile.<\/p>\n

This is the first direct comparison between the two oral GLP 1 obesity treatments as Eli Lilly prepares to launch Foundayo in the United States.<\/p>\n

For investors watching CPSE:NOVO B, this data arrives at a time when Novo Nordisk\u2019s share price stands at DKK236.9 and longer term returns have been mixed. The stock is up 3.7% over the past week, the 1 year return shows a 42.6% decline, and the 5 year return sits at 20.2%. Those swings underline how sensitive sentiment has been to developments in the obesity drug space.<\/p>\n

The fresh Wegovy data sets up a head to head contest in oral GLP 1 treatments that could shape how physicians and patients think about efficacy and tolerability. As both companies expand their obesity franchises, market share may be influenced by real world outcomes, patient adherence, and how payers respond to differences in clinical profiles and treatment preferences.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Apr 2026 <\/p>\n

We’ve flagged 5 risks for Novo Nordisk. See which could impact your investment.<\/a><\/p>\n

\u2705 Price vs Analyst Target: At DKK236.9, the share price sits about 24% below the DKK309.8 analyst target range midpoint.<\/p>\n

\u2705 Simply Wall St Valuation: The stock is flagged as trading around 68% below an estimated fair value.<\/p>\n

\u274c Recent Momentum: The 30 day return is roughly 3.5% lower, which points to short term weakness despite the new data.<\/p>\n

There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.<\/p>\n

\ud83d\udcca The Wegovy versus Foundayo data goes straight to the heart of the obesity franchise, as it touches on weight loss outcomes, tolerability and patient preference.<\/p>\n

\ud83d\udcca Watch physician adoption trends, any updates on payer coverage and how quickly oral GLP 1 scripts scale against the current market expectations.<\/p>\n

\u26a0\ufe0f Key risks include intense competition with Eli Lilly, a highly volatile share price over the past 3 months and identified concerns around debt, dividend cover and insider selling.<\/p>\n

For the full picture, including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can visit the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":759,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,30257,3754,272,30256,948],"class_list":["post-54586","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-global-community","tag-individual-investors","tag-novo-nordisk","tag-patient-preference","tag-share-price"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116339788060486947","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=54586"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/759"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=54586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=54586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=54586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}